Recent Finacing
Recent Raise
Flamingo Therapeutics develops RNA-targeted oncology therapies, advancing danvatirsen (STAT3 antisense) in Phase II—including a danvatirsen+pembrolizumab trial for HNSCC—and prepping FTX-001 (MALAT‑1 lncRNA) for Phase I in solid tumors.
